Céleste Lebbé

发表

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Ying Zhang, Jean-Jacques Grob, Keith T Flaherty, 2017, The Lancet. Oncology.

Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS

Isabelle Madelaine, Catherine Thieblemont, C. Lebbé, 2017, Therapeutic drug monitoring.

ZEB1‐mediated melanoma cell plasticity enhances resistance to MAPK inhibitors

Marie Perier-Muzet, Maxime Battistella, Arnaud de la Fouchardière, 2016, EMBO molecular medicine.

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.

Dirk Schadendorf, Axel Hauschild, Antoni Ribas, 2019, European journal of cancer.